You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Pharming Group belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same ...

Pharming Group excels with RUCONEST and JOENJA, showing strong revenue growth and positive cash flow. Check out my recommendation for PHAR stock.

Pharming Group delivered strong financial results in Q4 2024 and provided an optimistic 2025 revenue guidance of $315 million ...

adding KL1333 for mitochondrial DNA-driven primary mitochondrial diseases to Pharming’s late-stage clinical pipeline, in line with our vision to become a leading global rare disease company ...

That makes leniolisib important for Pharming's future growth prospects while it works on new uses for Ruconest in areas like acute kidney injury and a gene therapy for HAE partnered with Orchard ...

Across the recent three months, 4 analysts have shared their insights on Pharming (NASDAQ:PHAR), expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their ...

A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website. For more information about these conferences ...

Pharming Group has a 52-week low of $6.65 and a 52-week high of $11.94. The stock has a market capitalization of $541.53 million, a P/E ratio of -30.62 and a beta of -0.10. Get Pharming Group alerts: ...

Leiden, the Netherlands, April 3, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ...

Pharming's patient-finding efforts are continuing ... A significant challenge in diagnosing APDS patients occurs when a patient's genetic test result shows a VUS, or a variant of unknown significance.

The latest price target for Pharming (NASDAQ:PHAR) was reported by HC Wainwright & Co. on March 21, 2025. The analyst firm set a price target for $37.00 expecting PHAR to rise to within 12 months ...